Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - IMMUNE PHARMACEUTICALS INC | Financial_Report.xls |
| EX-32.1 - CERTIFICATION - IMMUNE PHARMACEUTICALS INC | v385001_ex32-1.htm |
| EX-10.4 - EXHIBIT 10.4 - IMMUNE PHARMACEUTICALS INC | v385001_ex10-4.htm |
| EX-31.1 - CERTIFICATION - IMMUNE PHARMACEUTICALS INC | v385001_ex31-1.htm |
| EX-31.2 - CERTIFICATION - IMMUNE PHARMACEUTICALS INC | v385001_ex31-2.htm |
| 10-Q - 10-Q - IMMUNE PHARMACEUTICALS INC | v385001_10q.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Immune Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel G. Teper, Principal Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C § 1350, as adopted pursuant to § 906 of the Sarbanes –Oxley Act of 2002, that:
| 1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Daniel G. Teper | |
| Daniel G. Teper | |
| Principal Financial Officer and Principal Accounting Officer |
|
| August 13, 2014 |